CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 202 enrolled
Drug / intervention
NSAID +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01958320
NCT01958320Phase 2Completed

Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus in Preterm infants-a Multicenter Trial

University of California, San Francisco·interventional·Posted Oct 9, 2013·Updated Nov 30, 2018

In Brief

A Phase 2 clinical trial evaluating pharmacologic treatment of the PDA, no pharmacologic treatment of the PDA, and 1 other intervention for Patent Ductus Arteriosus and 3 related conditions. Completed, enrolled 202 participants across 18 sites in 4 countries.

Detailed Summary

The primary goal of the trial is to compare two different Patent Ductus Arteriosus (PDA) treatment approaches: 1) an "early treatment" approach or 2) a "conservative" approach. For the purposes of the study infants will be enrolled if they are delivered before 28 weeks gestation and have a moderate/large PDA present at 5-7 days after birth. The hypothesis is: treatment of a moderate size patent ductus arteriosus (PDA) will decrease the time needed for assisted respiratory support, diuretic therapy, and gavage feeding assistance, in addition to decreasing the incidence of ductus ligations or need for future outpatient cardiology follow-up appointments. The investigators hypothesize that one or more of these benefits will occur without an increase in the time taken to achieve full enteral feedings or in the incidence of necrotizing enterocolitis (NEC) or spontaneous intestinal perforations (SIP).The investigators will be comparing the effectiveness of early pharmacologic treatment with a control group of conservatively managed infants who will only receive treatment if they meet specific criteria for "rescue treatment".

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSweden, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 9, 2013
Enrollment StartDec 1, 2013
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12.7 years ago

Interventions

pharmacologic treatment of the PDAother

Following randomization, infants will be treated with medications used to produce PDA closure.

no pharmacologic treatment of the PDAother

Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).

NSAIDdrug

Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment